Anglo-Swedish drugmaker AstraZeneca Plc said on Thursday it would pay $775 million to settle a patent dispute with Japan's Chugai Pharmaceutical involving lucrative rare disease treatment Ultomiris. Both AstraZeneca and Chugai will withdraw patent infringement cases filed in the US and Japan dating back to 2018 as part of the settlement, the London-listed company said in a statement. AstraZeneca will book the settlement payment as a charge in its first-quarter results. The payment won't affect its annual financial forecasts.